natgillin/translations-raw huggingface dataset:
Bz= Bortezomib Accord; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated. b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles
Bz= Bortezomib Accord; Dx=deksametasoon; T=talidomiid a Alates 1. tsükli 3. nädalast suurendatakse talidomiidi annust 100 mg-ni, kuid ainult juhul kui annus 50 mg oli hästi talutav ja alates 2. tsüklist 200 mg-ni, juhul kui annus 100 mg oli hästi talutav b Patsientidele, kellel pärast 4 ravitsüklit on saavutatud vähemalt osaline ravivastus, manustatakse kuni 6 ravitsüklit.
Bz= bortezomib; Dex=dexamethasone
CI= usaldusintervall
Bzmb (1.3 mg/m2)
Bzmb (1,3 mg/m2)
Bzmb n=193
Bzmb n = 193
Bzmb n=202a
Bzmb n = 202a
Bzmb n=315c
Bzmb n = 315c
Bzmb n=333a
Bzmb n = 333a
Bzmb+M+P n=344
Bzmb+M+P n = 344
Bzmb=Bortezomib SUN; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated. b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles
Bzmb = Bortezomib SUN; Dx = deksametasoon; T = talidomiid a Alates 1. tsükli 3. nädalast suurendatakse talidomiidi annust 100 mg-ni, kuid ainult juhul, kui annus 50 mg oli hästi talutav, ja alates 2. tsüklist 200 mg-ni, juhul kui annus 100 mg oli hästi talutav b Patsientidele, kellel pärast 4 ravitsüklit on saavutatud vähemalt osaline ravivastus, manustatakse kuni 6 ravikuuri.
Bzmb=Bortezomib SUN; M=melphalan, P=prednisone
Ravivaba periood
BzmbR-CAP (N=240)
BzmbR-CAP (N = 240)
BzmbR-CAP=bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
BzmbR-CAP = bortesomiib, rituksimab, tsüklofosfamiid, doksorubitsiin ja prednisoon; R-CHOP = rituksimab, tsüklofosfamiid, doksorubitsiin, vinkristiin ja prednisoon; PN = perifeerne neuropaatia
BzmbTDx (N=130)
TDx (N = 126)
BzR-CAP=Bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
BzR-CAP=bortesomiib, rituksimab, tsüklofosfamiid, doksorubitsiin ja prednisoon; R-CHOP = rituksimab, tsüklofosfamiid, doksorubitsiin, vinkristiin ja prednisoon; PN = perifeerne neuropaatia
C (n=1), D (n=66), and the circulating recombinant forms (CRFs) AD (n=9), CD (n=1), and a complex inter-subtype recombinant_cpx (n=1), a second study of 18 isolates including subtype G (n=14) and CRF_AG (n=4) from Nigeria, and a third study of six isolates (n=4 CRF_AG, n=1 A and n=1 undetermined) from Abidjan (Côte d'Ivoire).
C (n=1), D (n=66) ja tsirkuleerivaid rekombinantseid vorme (CRF, circulating recombinant form) AD (n=9), CD (n=1) ja keerukat subtüüpidevahelist rekombinanti cpx (n=1); teine 18 isolaadiga uuring Nigeerias sisaldas alatüüpe G (n=14) ja CRF_AG (n=4) ja kolmas 6 isolaadiga uuring (n=4 CRF_AG, n=1 A ja n=1 määramata tüvi) toimus Abidjan’is (Côte d'Ivoire’is).
c 48 weeks of double-blind adefovir dipivoxil followed by 48 weeks open-label tenofovir disoproxil fumarate. d The population used for analysis of ALT normalisation included only patients with ALT above ULN at baseline.
c 48 nädalat kestnud topeltpime uuring adefoviirdipivoksiiliga, millele järgnes 48 nädalat kestnud avatud uuring tenofoviirdisoproksiilfumaraadiga. d ALAT taseme normaliseerumise analüüsimiseks kasutatud populatsiooni kuulusid ainult patsiendid, kelle ALAT taseme algväärtus oli üle normaalse taseme ülempiiri.
C 60 mg/m2 i.v., days 22-25, 29-32
22. kuni 25.  ja 29. kuni 32. päeval.
C 60 mg/m2 i.v., days 22-25, 29-32
500 mg/m2 i.v.(1 h) päev 1; Ara- C 60 mg/m2 i.v., päevadel 22-25, 29-32
c > 48 hours of diarrhoea and/or > 7 days of rash d If patient cannot tolerate 20 mg/day, permanent discontinuation of GIOTRIF should be considered
c > 48 tundi kõhulahtisust ja/või > 7 päeva löövet d Kui patsient ei talu annust 20 mg/päevas, tuleb kaaluda GIOTRIFiga ravi püsivat lõpetamist
c Adverse reaction observed with Rasilamlo; a Adverse reaction observed with monotherapy with aliskiren; am Adverse reaction observed with monotherapy with amlodipine;
c Rasilamlo’ga täheldatud kõrvaltoimed a Aliskireeni monoteraapiaga täheldatud kõrvaltoimed; am Amlodipiini monoteraapiaga täheldatud kõrvaltoimed;
C Adverse reaction originates from saxagliptin or dapagliflozin post-marketing surveillance data.
C Kõrvaltoimed põhinevad saksagliptiini või dapagliflosiini turuletuleku järgsetel andmetel.
c CANCIDAS is formulated to provide the full labelled vial dose (50 mg) when 10 ml is withdrawn from the vial.
CANCIDAS’e kogu viaali sildil märgitud annuse (50 mg) saab siis, kui viaalist eemaldada 10 ml.
c CANCIDAS is formulated to provide the full labelled vial dose (70 mg) when 10 ml is withdrawn from the vial.
CANCIDAS’e kogu viaali sildil märgitud annuse (70 mg) saab siis, kui viaalist eemaldada 10 ml.
c Caspofungin Accord is formulated to provide the full labeled vial dose (50 mg) when 10 mL is withdrawn from the vial.
Caspofungin Accord’i kogu viaali sildil märgitud annuse (50 mg) saab siis, kui viaalist eemaldada 10 ml.
c Clearance and Volume of distribution in paediatric patients were calculated weight-adjusted from both 10 mcg /kg and 20 mcg /kg dose groups combined.
c Lastel on kliirens ja jaotusruumala kehakaalu suhtes kohandatud ja arvutatud 10 mikrogrammi/kg ja 20 mikrogrammi/kg annuserühmade kohta kokku.
C Difference is Eylea group minus active control (laser) group
C Erinevus on Eylea-rühma väärtus miinus võrdleva ravirühma (laser) väärtus.
c Duration of response as assessed by an Independent Review Committee d Kaplan-Meier estimate e Assessed by investigator
c Ravivastuse kestus, hinnatuna sõltumatu hindamiskogu poolt d Kaplan-Meieri hinnang e Uurija poolt hinnatud
c For AP and BP patients, 2-year data is not provided as minimum follow-up time is 12 and 18 months respectively. d Sample size (N) includes patients with a valid baseline haematologic assessment.
MCyR-i. c Aktseleratsiooni- ja blastses faasis KML-iga patsientide puhul ei ole esitatud 2 aasta andmeid, sest minimaalne jälgimisaeg on vastavalt 12 ja 18 kuud. d Valimi suurus (N) hõlmab valiidse esialgse hematoloogilise hindamisega patsiente.
c Includes patients who were evaluable for response
c Sisaldab patsiente, kes sobisid ravivastuse hindamiseks
c including drug hypersensitivity, angioedema, bronchospasm, wheezing, dyspnoea, and laryngospasm
c sealhulgas ülitundlikkus ravimi suhtes, angioödeem, bronhospasm, hingeldus, düspnoe ja larüngospasm
C OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
MÜÜGILOA MUUD TINGIMUSED JA NÕUDED
c p < 0.001, for each infliximab treatment group vs. control
c p < 0,001, iga infliksimabi grupi puhul vs. kontroll
c p < 0.01 compared with placebo d Patients with Itch NRS > = 4 at baseline: placebo N = 135, Taltz 80 mg Q4W N = 293, Taltz 80 mg Q2W N = 303, Etanercept N = 306
c p < 0,01 võrreldes platseeboga d Patsiendil sügeluse NRS > = 4 lähtemomendil: platseebo N = 135, Taltz 80 mg Q4W N = 293, Taltz 80 mg Q2W N = 303, etanertsept N = 306
c p = 0.002 d PedsQL: The PedsQL Total Scale Score is a general health-related quality of life measure developed for use in children and adolescent populations.
c p = 0,002 d PedsQL: PedsQL on üldine tervisega seotud elukvaliteedi mõõde, mis on välja töötatud kasutamiseks lastel ja noorukitel.
C p<0.05
C p < 0,05
C p<0.05
C p<0,05
c P=0.083, Humira 0.8 mg/kg versus MTX
c P = 0,083, Humira 0,8 mg/kg versus MTX
c P=0.083, Humira 0.8 mg/kg versus MTX
c P=0,083, Humira 0,8 mg/kg versus MTX
c Severe infections are those requiring or prolonging hospitalisation.
3-kuuline haiglaravi periood vahetult
C Subjects (N=22)
hepatiidiga
C Subjects (N=24)
hepatiidiga
c vertigo (spinning feeling);
vertiigo (peapööritus);
C&M Veterinary Distributors Limited IE-Limerick
Ed13-Piso 1- Esc.3 Quinta da Beloura 2710-693 Sintra
C) BCVA: Best Corrected Visual Acuity
C) BCVA: Best Corrected Visual Acuity, parim korrigeeritud nägemisteravus.
C) LS mean: Least square means derived from ANCOVA model
C) LS mean: Least Square mean, vähimruutude keskmine ANCOVA alusel.
C) The difference is the value of the Eylea group minus the value of the ranibizumab group.
C) Erinevus on Eylea-rühma väärtus miinus ranibizumabi-rühma väärtus.
C-cell hyperplasia and adenoma were seen at all doses in rats and a no observed adverse effect level (NOAEL) could be not defined.
C-rakkude hüperplaasiat ja adenoomi täheldatirottidel kõikide annuste korral ning taset, mille puhul kõrvaltoimeid ei teki (ingl no observed adverse effect level, NOAEL) ei olnud võimalik määratleda.
C-EARLY
C- EARLY
C-EDGE COINFECTION
C-EDGE
C-EDGE TE
C-SALVAGE
C-reactive protein increased
C-reaktiivse valgu sisalduse suurenemine
C-reactive protein increased
C-reaktiivse valgu taseme tõus
C-reactive protein increased Blood calcium decreased
C-reaktiivse valgu tõus
C-reactive protein increased Blood calcium decreased
C-reaktiivse valgu tõus Hüpokaltseemia
c-reactive protein increased, blood parathyroid hormone increased
C-reaktiivse valgu taseme tõus, kõrvalkilpnäärmehormooni taseme tõus veres
C-reactive protein, mg/l
C-reaktiivne valk, mg/l
C-SCAPE
C-WORTHY
C-SURFER
maksatsirroosi
C-WORTHY
C-SURFER
C. After the second “click” (or count of 15) lift pre-filled pen from the injection site.
C. Kui kuulete teist klõpsu (või olete lugenud 15-ni), tõstke eeltäidetud pensüstel süstimiskohalt.
C. Due to the lack of data in children with severe progression of the disease, and the potential for undesirable effects, the benefit/risk of the combination of ribavirin and pegylated interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8).
Kuna puuduvad andmed raske progresseeruva haigusega laste ja võimalike kõrvaltoimete kohta, tuleb selle populatsiooni puhul ribaviriini ja pegüleeritud alfa-2b-interferoon kombinatsioonravi kasu ja ohu vahekorda hoolikalt hinnata (vt lõigud 4.1, 4.4 ja 4.8).
C. glabrata, the MICs of voriconazole for fluconazole-resistant isolates are proportionally higher than are those of fluconazole-susceptible isolates.
Konkreetselt on C. glabrata flukonasooliresistentsete isolaatide korral vorikonasooli minimaalselt inhibeeriv kontsentratsioon suurem kui flukonasoolitundlikel isolaatidel.
C. In all four studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 12 weeks after the end of treatment.
Kõigis neljas uuringus oli efektiivsuse põhinäitaja patsientide arv, kelle vereanalüüsis ei leitud 12 nädalat pärast ravi lõppu C-hepatiidi viirust.
C. inconspicua, and C. guilliermondii, Scedosporium spp., including S. apiospermum, S. prolificans; and
inconspicua,ja C. guillermondii; Scedosporium spp., kaasa arvatud S. apiospermum, S. prolificans, ja
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi ja Fusarium, Rhizomucor, Mucor ja Rhizopus spp.
C. krusei (7 patients), and C. parapsilosis (6 patients).
C. parapsilosis (6 patsienti).
C. Osi, 7
Osi, 7
C. perfringens type C toxoid ≥ 20 IU
C. perfringens tüüp C toksoid ≥ 20 RÜ
C. perfringens type C toxoid ≥ 20 IU dl--tocopheryl acetate
C. perfringens tüüp C toksoid ≥ 20 RÜ dl--tokoferüülatsetaat
C. The vaccine is used to reduce death and clinical signs of infections caused by these bacteria during the first days of life.
Vaktsiini kasutatakse selleks, et vähendada nende bakterite põhjustatud infektsioonidest tingitud surmajuhtumeid ja kliinilisi nähte põrsaste esimestel elupäevadel.
C. Your doctor may evaluate how severe your liver disease is before deciding if you can take INTELENCE.
Võib- olla peab arst teie maksahaiguse tõsidust hindama, enne kui otsustab, kas saate INTELENCE’i võtta.
c.1001 G>A
c.979 C>G
c.1012 G>A
c.983 G>C
c.1012 G>T
c.997 C>T
c.1016 T>A
c.1001 G>A
c.1016 T>G
c.998 A>G
c.1018 T>C
c.1012 G>T
c.1028 C>T
c.1012 G>A
c.1033 T>C
c.1016 T>A
c.1046 G>C
c.1028 C>T
c.1055 C>T
c.1033 T>C
c.1061 T>A
c.1046 G>C
c.1066 C>G
c.1055 C>T
c.1066 C>T
c.1061 T>A
c.1067G>A
c.1066 C>G
c.1067G>C
c.1066 C>T
c.1073 A>C
c.1067G>A
c.1073 A>G
c.1067G>C
c.1074 G>T
c.1073 A>C
c.1076 T>C
c.1073 A>G
c.1078 G>A
c.1074 G>T
c.1078 G>T
c.1076 T>C
c.1079 G>A
c.1078 G>A
c.1082 G>A
c.1078 G>T
c.1082 G>C
c.1079 G>A
c.1084 C>A
c.1082 G>A
c.1085 C>T
c.1082 G>C
c.1087 C>T
c.1084 C>A
c.1088 G>A
c.1085 C>T
c.1102 G>A
c.1087 C>T
c.1117 G>A
c.1088 G>A
c.118 C>G
c.71 G>A
c.118 C>T
c.92 C>T
c.1196 G>A or1197 G>A
c.1196 G>A või 1197 G>A
c.140 G>A or 141 G>A
c.140 G>A või 141 G>A
c.156 C>A
c.155 G>A
c.156 C>G
c.156 C>A
c.166 T>G
c.156 C>G
c.167 G>C
c.166 T>G
c.168 C>A
c.167 G>C
c.187 T>C
c.168 C>A
c.188 G>A
c.187 T>C
c.188 G>C
c.188 G>A
c.194 G>T (putative splicing site )
c.194 G>C (oletatav splaissingusait)
c.215 T>G
c.196 G>C
c.218 C>A
c.202 C>T
c.227 T>G
c.215 T>G
c.233 C>G
c.218 C>A
c.235 G>T
c.227 T>G
c.241 T>C
c.233 C>G
c.242 G>A
c.235 G>T
c.242 G>C
c.241 T>C
c.243 G>T
c.242 G>A
c.244 A>T
c.242 G>C
c.256 T>C
c.244 A>T
c.256 T>G
c.243 G>T
c.257 A>G
c.256 T>G
c.258 T>G
c.256 T>C
c.262 T>G
c.257 A>G
c.266 T>C
c.258 T>G
c.266 T>G
c.262 T>G
c.268 T>C
c.266 T>C
c.269 G>A
c.266 T>G
c.270 C>A
c.268 T>C
c.274 G>A
c.270 C>A
c.274 G>C
c.269 G>A
c.274 G>T
c.274 G>C
c.275 A>G
c.274 G>A
c.275 A>T
c.274 G>T
c.277 G>A
c.275 A>G
c.277 G>T
c.275 A>T
c.278 A>G
c.277 G>A
c.278 A>T
c.277 G>T
c.279 C>G
c.278 A>G
c.280T>G
c.278 A>T
c.281 G>A
c.280T>G
c.281 G>C
c.279 C>G
c.284 G>A
c.281 G>C
c.284 G>C
c.284 G>A
c.284 G>T
c.281 G>A
c.295 C>T
c.284 G>T
c.299 G>A
c.284 G>C
c.299 G>C
c.295 C>T
c.305 C>G
c.299 G>A
c.307 G>C
c.299 G>C
c.307 G>T
c.305 C>G
c.317 T>G
c.307 G>C
c.319 C>T
c.307 G>T
c.320 A>T
c.317 T>G
c.334 C>A
c.320 A>T
c.334 C>T
c.319 C>T
c.338 T>C
c.334 C>T
c.350 T>G
c.334 C>A
c.355 C>T
c.338 T>C
c.358 C>G
c.350 T>G
c.359 T>C
c.358 C>G
c.361 G>C
c.[358 C>T; 359 T>C]
c.37 G>C
c.43 G>A
c.371 T>A
c.359 T>C
c.374 A>C
c.361 G>C
c.379 A>T
c.371 T>A
c.386 T>C
c.374 A>C
c.389 A>G
c.379 A>T
c.392 T>C
c.386 T>C
c.394 G>A
c.389 A>G
c.395 G>A
c.392 T>C
c.395 G>C
c.394 G>A
c.398T>A
c.395 G>A
c.400 T>C
c.395 G>C
c.400 T>G
c.398T>A
c.401 A>C
c.400 T>C
c.402 T>G
c.400 T>G
c.406 G>C
c.401 A>C
c.406 G>T
c.402 T>G
c.412 G>A
c.406 G>C
c.413 G>A
c.406 G>T
c.416 A>C
c.412 G>A
c.422 C>A
c.413 G>A
c.422 C>T
c.416 A>C
c.424 T>C
c.422 C>A
c.425 G>A
c.422 C>T
c.426 C>A
c.424 T>C
c.426 C>G
c.425 G>A
c.427 G>C
c.426 C>A
c.43 G>A
c.44 C>G
c.439 G>A
c.426 C>G
c.44 C>G
c.58 G>C
c.440 G>A
c.427 G>C
c.443 G>A
c.439 G>A
c.444 T>G
c.440 G>A
c.453 C>G
c.443 G>A
c.456 C>A
c.444 T>G
c.463 G>C
c.453 C>G
c.467 C>A
c.456 C>A
c.469 C>T
c.463 G>C
c.47 T>C
c.47 T>A
c.484 T>C
c.467 C>A
c.485 G>A
c.469 C>T
c.485 G>T
c.484 T>C
c.486 G>C
c.485 G>A
c.488 G>T
c.485 G>T
c.491 T>G
c.486 G>C
c.493 G>T
c.488 G>T
c.494 A>T
c.491 T>G
c.500 T>A
c.493 G>T
c.500 T>C
c.494 A>T
c.503 A>G
c.500 T>A
c.504 A>C
c.500 T>C
c.508 G>A
c.503 A>G
c.508 G>C
c.504 A>C
c.53 T>C
c.47 T>C
c.547 G>A (putative splicing site )
c.547 G>A (oletatav splaissingusait)
c.559_564 dup
c.560 T>C
c.559_564dup
c.T560C
c.561 G>T
c.559 A>G
c.58 G>C
c.59 C>A
c.581 C>T
c.559_564 dup
c.584 G>T
M187_S188 dup
c.59 C>A
c.70 T>C
c.593 T>C
c.581 C>T
c.595 G>A
c.584 G>T
c.596 T>G
c.593 T>C
c.599 A>G
c.595 G>A
c.602 C>A
c.599 A>G
c.602 C>T
c.596 T>G
c.608 A>T
c.602 C>T
c.609 G>C
c.602 C>A
c.611 G>A or 612G>A
c.611 G>A või 612G>A
c.613 C>A
c.608 A>T
c.613 C>T
c.609 G>C
c.614 C>T
c.613 C>A
c.619 T>C
c.613 C>T
c.620 A>C
c.614 C>T
c.628 C>T
c.619 T>C
c.629 C>T
c.620 A>C
c.638 A>T
c.628 C>T
c.640 C>T
c.629 C>T
c.641 C>T
c.638 A>T
c.641T
c.A638T
c.643 A>G
c.640 C>T
c.644 A>G
c.641 C>T
c.647 A>G
c.[644 A>G; 937 G>T]
c.656 T>A
c.646 T>G
c.656 T>C
c.647 A>G
c.659 G>A
c.656 T>A
c.659 G>C
c.656 T>C
c.671 A>G
c.659 G>A
c.673 C>G
c.659 G>C
c.683 A>G
c.671 A>G
c.687 T>A
c.673 C>G
c.688 G>A
c.680 G>A
c.691 G>A
c.680 G>C
c.692 A>G
c.688 G>A
c.692 A>T
c.691 G>A
c.695 T>C
c.683 A>G
c.70 T>C
c.70 T>G
c.70 T>G
c.72 G>C
c.700 G>T
c.692 A>G
c.702 T>G
c.692 A>T
c.71 G>A
c.62 T>C
c.713 G>A
c.687 T>A
c.716 T>C
c.695 T>C
c.72 G>C
c.95 T>C
c.724 A>T
c.713 G>A
c.725 T>A
c.716 T>C
c.728 T>G
c.725 T>A
c.729 G>C
c.724 A>T
c.730 G>A
c.729 G>C
c.730 G>C
c.728 T>G
c.734 G>A or 735G>A
c.734 G>A või 735G>A
c.735 T>G
c.730 G>A
c.740 C>G
c.730 G>C
c.747 C>G
c.735 T>G
c.749 A>C
c.740 C>G
c.758 T>C
c.747 C>G
c.758 T>G
c.749 A>C
c.760-762del GTT
c.758 T>C
c.760_762delGTT
c.T758C
c.769 G>C
c.758 T>G
c.770 C>G
c.760-762del GTT
c.772 G>C
c.769 G>C
c.773 G>T
c.770 C>G
c.776 C>G
c.772 G>C
c.776 C>T
c.773 G>T
c.801 G>A (putative splicing site )
c.801 G>A (oletatav splaissingusait)
c.835 C>A
c.826 A>G
c.836 A>G
c.830 G>A
c.837 G>C
c.835 C>A
c.860 G>A or 861G>A
c.860 G>A või 861G>A
c.897 C>G
c.888 G>A
c.898 C>T
c.893 A>G
c.899 T>C
c.897 C>G
c.901 C>G
c.898 C>T
c.902 G>A
c.901 C>G
c.902 G>C
c.899 T>C
c.902 G>T
c.902 G>C
c.908 T>A
c.902 G>A
c.911 G>A
c.902 G>T
c.911 G>C
c.908 T>A
c.919 G>A
c.911 G>A
c.92 C>T
c.62 T>G
c.924 A>T
c.911 G>C
c.925 G>C
c.919 G>A
c.928 C>T
c.924 A>T
c.931 C>G
c.925 G>C
c.935 A>G
c.928 C>T
c.936 G>T
c.931 C>G
c.937 G>T
c.935 A>G
c.938 A>G
c.936 G>T
c.946 G>A
c.937 G>T
c.947 T>G
c.938 A>G
c.95 T>C
c.97 G>T
c.950 T>C
c.946 G>A
c.955 A>T
c.947 T>G
c.956 T>C
c.950 T>C
c.959 A>T
c.955 A>T
c.962 A>G
c.956 T>C
c.962 A>T
c.959 A>T
c.963 G>C
c.962 A>G
c.964 G>C
c.962 A>T
c.966 C>A
c.963 G>C
c.97 G>T
c.98 A>G
c.973 G>A
c.964 G>C
c.973 G>C
c.966 C>A
c.979 C>G
c.973 G>A
c.983 G>C
c.973 G>C
c.983 G>T
c.982 G>T
c.988 C>T
c.983 G>A
c.997 C>T
c.983 G>T
c.998 A>G
c.988 C>T
c.[358 C>T; 359 T>C]
c.355 C>T
c.[644 A>G; 937 G>T]
c.643 A>G
C.A. Papaellinas Ltd.Τηλ: +357 22741741
Τηλ: +357 22741741
c.A1073C
c.G1067A
c.A1073G
c.G1067C
c.A244T
c.G242C
c.A257G
c.T256G
c.A275G
c.G274A
c.A275T
c.G274T
c.A278G
c.G277A
c.A278T
c.G277T
c.A320T
c.T317G
c.A374C
c.G361C
c.A379T
c.T371A
c.A389G
c.A379T
c.A401C
c.T400C
c.A416C
c.G412A
c.A494T
c.T491G
c.A503G
c.T500A
c.A504C
c.T500C
c.A599G
c.G595A
c.A608T
c.C602T
c.A620C
c.C614T
c.A638T
c.C628T
c.A643G
c.C640T
c.A644G
c.641T
c.A647G
A644G/G937T
c.A671G
c.G659A
c.A683G
c.A671G
c.A692G
c.G688A
c.A692T
c.G691A
c.A724T
c.G713A
c.A749C
c.C740G
c.A836G
c.G830A
c.A924T
c.G911C
c.A935G
c.C928T
c.A938G
c.G936T
c.A955T
c.T947G
c.A959T
c.A955T
c.A962G
c.T956C
c.A962T
c.A959T
c.A998G
c.C988T
c.C1028T
c.G1012A
c.C1055T
c.T1033C
c.C1066G
c.C1055T
c.C1066T
c.T1061A
c.C1084A
c.G1082A
c.C1085T
c.G1082C
c.C1087T
c.C1084A
c.C118G
c.G71A
c.C118T
c.C92T
c.C156A
c.G155A
c.C156G
c.C156A
c.C168A
c.G167C
c.C218A
c.C202T
c.C233G
c.C218A
c.C270A
c.T268C
c.C279G
c.A278G
c.C295T
c.G284T
c.C305G
c.G299A
c.C319T
c.G307T
c.C334A
c.A320T
c.C334T
c.C319T
c.C355T
c.T338C
c.C358G
c.T350G
c.C358T/T359C
c.C355T
c.C422A
c.G413A
c.C422T
c.A416C
c.C426A
c.T424C
c.C426G
c.G425A
c.C44G
c.G58C
c.C453G
c.G443A
c.C456A
c.T444G
c.C467A
c.C456A
c.C469T
c.G463C
c.C581T
c.559_564dup
c.C59A
c.T70C
c.C602A
c.A599G
c.C602T
c.T596G
c.C613A
c.A608T
c.C613T
c.G609C
c.C614T
c.C613A
c.C628T
c.T619C
c.C629T
c.A620C
c.C640T
c.C629T
c.C673G
c.G659C
c.C740G
c.G730C
c.C747G
c.T735G
c.C770G
c.760_762delGTT
c.C776G
c.G772C
c.C776T
c.G773T
c.C835A
c.A826G
c.C897G
c.G888A
c.C898T
c.A893G
c.C901G
c.C898T
c.C928T
c.A924T
c.C92T
c.T62G
c.C931G
c.G925C
c.C966A
c.G963C
c.C979G
c.G973A
c.C988T
c.G983A
c.C997T
c.G983T
c.G1001A
c.C979G
c.G1012A
c.G983C
c.G1012T
c.C997T
c.G1046C
c.C1028T
c.G1067A
c.C1066G
c.G1067C
c.C1066T
c.G1074T
c.A1073C
c.G1078A
c.G1074T
c.G1078T
c.T1076C
c.G1079A
c.G1078A
c.G1082A
c.G1078T
c.G1082C
c.G1079A
c.G1088A
c.C1085T
c.G1102A
c.C1087T
c.G1117A
c.G1088A
c.G1196A or G1197A
c.G1196A või G1197A
c.G155A
c.G155C
c.G167C
c.T166G
c.G188A
c.T187C
c.G188C
c.G188A
c.G194T (putative splicing site )
c.G194C (oletatav splaissingusait)
c.G235T
c.T227G
c.G242A
c.G235T
c.G242C
c.T241C
c.G243T
c.G242A
c.G253A
c.G247A
c.G269A
c.T266G
c.G274A
c.C270A
c.G274C
c.G269A
c.G274T
c.G274C
c.G277A
c.A275G
c.G277T
c.A275T
c.G281A
c.T280G
c.G281C
c.C279G
c.G284A
c.G281C
c.G284C
c.G284A
c.G284T
c.G281A
c.G299A
c.G284C
c.G299C
c.C295T
c.G307C
c.G299C
c.G307T
c.C305G
c.G361C
c.C358T/T359C
c.G37C
c.G43A
c.G394A
c.A389G
c.G395A
c.T392C
c.G395C
c.G394A
c.G406C
c.A401C
c.G406T
c.T402G
c.G412A
c.G406C
c.G413A
c.G406T
c.G425A
c.C422T
c.G427C
c.C426A
c.G439A
c.C426G
c.G43A
c.C44G
c.G440A
c.G427C
c.G443A
c.G439A
c.G463C
c.C453G
c.G485A
c.C469T
c.G485T
c.T484C
c.G486C
c.G485A
c.G488T
c.G485T
c.G493T
c.G488T
c.G508A
c.A503G
c.G508C
c.A504C
c.G547A (putative splicing site )
c.G547A (oletatav splaissingusait)
c.G561T
c.A559G
c.G584T
c.572 T>A
c.G58C
c.C59A
c.G595A
c.G584T
c.G609C
c.C602A
c.G659A
c.T656A
c.G659C
c.T656C
c.G688A
c.G680A
c.G691A
c.G680C
c.G700T
c.A692G
c.G713A
c.T687A
c.G71A
c.T62C
c.G729C
c.A724T
c.G72C
c.T95C
c.G730A
c.G729C
c.G730C
c.T728G
c.G734A or G735A
c.G734A või G735A
c.G769C
c.T758G
c.G772C
c.G769C
c.G773T
c.C770G
c.G837C
c.C835A
c.G860A or G861A
c.G860A või G861A
c.G902A
c.C901G
c.G902C
c.T899C
c.G902T
c.G902C
c.G911A
c.G902T
c.G911C
c.T908A
c.G919A
c.G911A
c.G925C
c.G919A
c.G936T
c.C931G
c.G937T
c.A935G
c.G946A
c.G937T
c.G963C
c.A962G
c.G964C
c.A962T
c.G973A
c.G964C
c.G973C
c.C966A
c.G983C
c.G973C
c.G983T
c.G982T
c.T1016A
c.G1001A
c.T1016G
c.A998G
c.T1033C
c.T1016A
c.T1061A
c.G1046C
c.T1076C
c.A1073G
c.T166G
c.C156G
c.T187C
c.C168A
c.T215G
c.G196C
c.T227G
c.T215G
c.T241C
c.C233G
c.T256C
c.A244T
c.T256G
c.G243T
c.T258G
c.T256C
c.T262G
c.A257G
c.T266C
c.T258G
c.T266G
c.T262G
c.T268C
c.T266C
c.T280G
c.A278T
c.T317G
c.G307C
c.T338C
c.C334T
c.T350G
c.C334A
c.T359C
c.C358G
c.T371A
c.T359C
c.T386C
c.A374C
c.T392C
c.T386C
c.T398A
c.G395A
c.T400C
c.G395C
c.T400G
c.T398A
c.T402G
c.T400G
c.T424C
c.C422A
c.T444G
c.G440A
c.T47A
c.G43C
c.T47C
c.T47A
c.T484C
c.C467A
c.T491G
c.G486C
c.T500A
c.G493T
c.T500C
c.A494T
c.T53C
c.T47C
c.T572A
c.G561T
c.T593C
c.C581T
c.T596G
c.T593C
c.T619C
c.C613T
c.T62G
c.C61T
c.T646G
c.A644G
c.T656A
c.T646G
c.T656C
c.A647G
c.T687A
c.C673G
c.T695C
c.A683G
c.T702G
c.A692T
c.T70C
c.T70G
c.T70G
c.G72C
c.T716C
c.T695C
c.T725A
c.T716C
c.T728G
c.T725A
c.T735G
c.G730A
c.T758C
c.C747G
c.T758G
c.A749C
c.T899C
c.C897G
c.T908A
c.G902A
c.T947G
c.A938G
c.T950C
c.G946A
c.T956C
c.T950C
c.T95C
c.G97T
C/ Batanes,
C/Batanes 1
C/ Del Sol 5, Polígono Industrial Norte Tres Cantos
C/ Del Sol, 5, Poligono Industrial Norte Tres Cantos
C/ Del Sol, 5, Poligono Industrial Norte, Tres Cantos, 28760, Madrid
C/ Del Sol, 5, Poligono Industrial Norte, Tres Cantos, 28760, Madrid HISPAANIA
C/ Mocholi 2, Poligono Industrial Mocholi, Noain, 31110 Navarra
C/ Mocholi 2, Poligono Industrial Mocholi, Noain, 31110 Navarra,
C/ Veguillas – 2 Nave 16, Ajalvir 28864 (Madrid) Spain
C/ Veguillas - 2 Nave 16, Ajalvir 28864 (Madrid) Hispaania
c/o Icepharma hf Sími: +354 540 8000
Roche a/s c/o Icepharma hf Tel: +354 540 8000
C0h (μg/ml)
C0h (µg/ml)
C1 inhibitor (human)
CI inhibiitor (inimpäritolu)
C1 inhibitor (human)
Cinryze inimese C1 inhibiitor
C1 inhibitor inhibits the complement system by binding C1r and C1s, two of the active enzyme subunits of the first component of the complement system (C1) in the classical pathway, as well as to mannose-binding lectin-associated serine proteases in the lectin pathway.
C1 inhibiitor pärsib komplemendi süsteemi, seondudes C1r-i ja C1s-iga, mis on komplemendi süsteemi esimese komponendi (C1) kaks aktiivset alaühikut klassikalise aktivatsiooni puhul, samuti inaktiveerib lektiini raja puhul mannoosi siduvaid lektiiniga seotud seriini proteaase.
C1 inhibitor is a member of the serine protease inhibitor, or serpin, superfamily of proteins.
C1 inhibiitor kuulub valkude seriini proteaasi inhibiitorite ehk serpiinide superperekonda.
C1 inhibitor is a naturally occurring protein that is normally present in the blood.
C1 inhibiitor on looduslik valk, mida normaalne veri sisaldab.
C1 inhibitor is a single chain glycoprotein found in plasma which, in its mature state, consists of 478 amino acids with an apparent molecular weight of 105 kD.
C1 inhibiitor on plasmas sisalduv ühe ahelaga glükovalk, mis küpsel kujul koosneb 478 aminohappest, mille näiv molekulmass on 105 kD.
C12 0.97 (0.81, 1.15)
C12 0,97 (0,81, 1,15)
C12 0.99 (0.80, 1.22)
C12 0,99 (0,80, 1,22)